LDL-c: Done Deal, Next Epigenetics?
EBAC accredited symposium to be held at ESC 2018Agenda - Aug. 25, 2018 - ESC 2018, Munich, Germany
If you are attending ESC congress 2018 in Munich, Germany, you are cordially invited to attend this symposium
Saturday, August 25, 2018: 15:30 – 16:30 hrs*
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes and CVD
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
- Introduction, Ulrich Laufs, MD, University of Leipzig Medical Center, Leipzig, Germany
- The real residual risk in patients with CVD & diabetes: The promise of epigenetics, Erik Stroes, MD, Academic Medical Centre, Amsterdam, The Netherlands
- Understanding Epigenetics: The potential rationale for BET inhibition in management of CVD, Jorge Plutzky, MD, Brigham & Women’s Hospital, Boston, USA
- A clinical view on BET inhibition in targeting residual risk in CVD and Diabetes , Kausik Ray, MD, Imperial College London, London, United Kingdom
- Panel discussion, Ulrich Laufs, MD, Kausik Ray, MD
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
Supported by an unrestricted educational grant from Resverlogix